Asli Bahar Ucar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Asli Bahar Ucar has a total of 160 co-authors. Here are the top co-authors by number of shared publications:
- Ozgur Karcioglu
Department of Emergency Medicine, University of Health Sciences, Istanbul Education and Research Hospital, Istanbul, Turkey
9 shared publications - Busra Erdem
Department of Emergency Medicine, Sisli Hamidiye Etfal Education and Research Hospital, University of Health Sciences, Istanbul, Türkiye
7 shared publications - Canan Akman
Department of Emergency Medicine, Canakkale Onsekiz Mart University, Canakkale, Turkey
6 shared publications - Bilgen Ozkaya
Department of Emergency Medicine, Losante Children’s and Adult Hospital, Ankara, Turkiye
5 shared publications - Arzu Denizbasi
Department of Emergency Medicine, Marmara University Faculty of Medicine, İstanbul, Türkiye
4 shared publications - Gökhan Yılmaz
Emergency Medicine, Konya Beyhekim Education and Research Hospital, Konya, Turkiye
4 shared publications
Latest Publications
- 10 November 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32
Ticagrelor in the Emergency Treatment of Acute Coronary Syndromes: A Comprehensive Clinical Review
Introduction/Objective: Acute Coronary Syndromes (ACS) — encompassing STEMI and NSTEACS — remain among the foremost causes of cardiovascular mortality worldwide. Ticagrelor, the first reversibly binding, direct-acting oral P2Y12 antagonist, has demonstrated superior efficacy over clopidogrel in landmark trials and carries a Class I recommendation in current international guidelines. This review provides a comprehensive, evidence-based appraisal of ticagrelor’s pharmacology, clinical efficacy, safety, and decision- making guidance in the emergency management of ACS. Methods: PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were searched from January 2005 to May 2026. A narrative synthesis prioritised meta-analyses, systematic reviews, and randomised controlled trials, including PLATO, ISAR-REACT 5, TWILIGHT, TICO, PEGASUS-TIMI 54, and GLOBAL LEADERS, alongside the 2023 ESC and 2025 ACC/AHA guidelines. Results: Ticagrelor significantly reduced cardiovascular death, myocardial infarction, and stroke versus clopidogrel (HR 0.84; p < 0.001) with a concomitant all-cause mortality benefit. Ticagrelor monotherapy after short dual antiplatelet therapy reduced major bleeding without increasing ischaemic events. Extended ticagrelor (60 mg twice daily) beyond 12 months reduced recurrent events in high-risk post-myocardial infarction patients. Plaque erosion pathobiology and neutrophil extracellular trap attenuation identify contexts in which ticagrelor may confer additional benefit. Discussion: Regimen selection requires integrating the culprit lesion phenotype, a two-axis ischaemichaemorrhagic risk framework, and an assessment of contraindications, drug interactions, and special populations, including elderly patients, those with renal impairment, and those requiring oral anticoagulation. Conclusion: Ticagrelor offers potent, reversible platelet inhibition with a favourable efficacy-safety balance across the ACS spectrum. Individualised, phenotype-guided therapy optimises outcomes and minimises harm.
- 10 November 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32
Ticagrelor in the Emergency Treatment of Acute Coronary Syndromes: A Comprehensive Clinical Review
Introduction/Objective: Acute Coronary Syndromes (ACS) — encompassing STEMI and NSTEACS — remain among the foremost causes of cardiovascular mortality worldwide. Ticagrelor, the first reversibly binding, direct-acting oral P2Y12 antagonist, has demonstrated superior efficacy over clopidogrel in landmark trials and carries a Class I recommendation in current international guidelines. This review provides a comprehensive, evidence-based appraisal of ticagrelor’s pharmacology, clinical efficacy, safety, and decision- making guidance in the emergency management of ACS. Methods: PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were searched from January 2005 to May 2026. A narrative synthesis prioritised meta-analyses, systematic reviews, and randomised controlled trials, including PLATO, ISAR-REACT 5, TWILIGHT, TICO, PEGASUS-TIMI 54, and GLOBAL LEADERS, alongside the 2023 ESC and 2025 ACC/AHA guidelines. Results: Ticagrelor significantly reduced cardiovascular death, myocardial infarction, and stroke versus clopidogrel (HR 0.84; p < 0.001) with a concomitant all-cause mortality benefit. Ticagrelor monotherapy after short dual antiplatelet therapy reduced major bleeding without increasing ischaemic events. Extended ticagrelor (60 mg twice daily) beyond 12 months reduced recurrent events in high-risk post-myocardial infarction patients. Plaque erosion pathobiology and neutrophil extracellular trap attenuation identify contexts in which ticagrelor may confer additional benefit. Discussion: Regimen selection requires integrating the culprit lesion phenotype, a two-axis ischaemichaemorrhagic risk framework, and an assessment of contraindications, drug interactions, and special populations, including elderly patients, those with renal impairment, and those requiring oral anticoagulation. Conclusion: Ticagrelor offers potent, reversible platelet inhibition with a favourable efficacy-safety balance across the ACS spectrum. Individualised, phenotype-guided therapy optimises outcomes and minimises harm.
- Open Access
- 20 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-3
Comment on evaluating clinical characteristics and outcomes associated with body stuffers presenting to the emergency department
- 20 October 2026
- Published by Taylor & Francis in Clinical Toxicology
- p. 1-3
Open AccessComment on evaluating clinical characteristics and outcomes associated with body stuffers presenting to the emergency department
- Open Access
- 10 October 2026
- Published by Wolters Kluwer Health in Turkish Journal of Emergency Medicine
- Vol. 26 (4) , 314-320
Early emergency department risk signals in upper gastrointestinal bleeding: The hemoglobin-to-red cell distribution width ratio
OBJECTIVES: Upper gastrointestinal bleeding (UGIB) is a common emergency associated with substantial morbidity and mortality. Early risk assessment is important, but some established scores require laboratory or endoscopic data not immediately available. We evaluated whether the hemoglobin (Hb)-to-red cell distribution width ratio (Hb/RDW) at emergency department presentation was associated with intensive care unit admission or mortality during the index episode. METHODS: This retrospective single-center study included adults presenting with UGIB between 2019 and 2023. Patients with incomplete evaluation, missing Hb or RDW values, or non-UGIB bleeding sources were excluded. Hb/RDW was calculated at presentation. Group comparisons, receiver operating characteristic analyses, and multivariable logistic regression were performed for the primary composite outcome. Additional adjusted models compared Hb/RDW with Hb and RDW individually. RESULTS: Among 942 patients, the primary composite outcome occurred in 121 (12.8%). Hb/RDW was lower in patients with the primary outcome (0.398 [0.296–0.539] vs. 0.568 [0.411–0.780]; P < 0.001). Discrimination was moderate (area under the curve: 0.712, 95% confidence interval [CI]: 0.664–0.757); a threshold near 0.593 yielded sensitivity 0.851 and negative predictive value 0.956. Hb/RDW remained independently associated with the primary outcome (adjusted odds ratio: 0.023, 95% CI: 0.007–0.073; P < 0.001). It performed better than Hb alone and similarly to RDW, with the greatest incremental discrimination when added to the clinical base model. Lower values were also observed in variceal bleeding. CONCLUSION: Lower Hb/RDW at presentation was independently associated with adverse outcomes in UGIB and may serve as an adjunctive early triage marker.
- 10 October 2026
- Published by Wolters Kluwer Health in Turkish Journal of Emergency Medicine
- Vol. 26 (4) , 314-320
Open AccessEarly emergency department risk signals in upper gastrointestinal bleeding: The hemoglobin-to-red cell distribution width ratio
OBJECTIVES: Upper gastrointestinal bleeding (UGIB) is a common emergency associated with substantial morbidity and mortality. Early risk assessment is important, but some established scores require laboratory or endoscopic data not immediately available. We evaluated whether the hemoglobin (Hb)-to-red cell distribution width ratio (Hb/RDW) at emergency department presentation was associated with intensive care unit admission or mortality during the index episode. METHODS: This retrospective single-center study included adults presenting with UGIB between 2019 and 2023. Patients with incomplete evaluation, missing Hb or RDW values, or non-UGIB bleeding sources were excluded. Hb/RDW was calculated at presentation. Group comparisons, receiver operating characteristic analyses, and multivariable logistic regression were performed for the primary composite outcome. Additional adjusted models compared Hb/RDW with Hb and RDW individually. RESULTS: Among 942 patients, the primary composite outcome occurred in 121 (12.8%). Hb/RDW was lower in patients with the primary outcome (0.398 [0.296–0.539] vs. 0.568 [0.411–0.780]; P < 0.001). Discrimination was moderate (area under the curve: 0.712, 95% confidence interval [CI]: 0.664–0.757); a threshold near 0.593 yielded sensitivity 0.851 and negative predictive value 0.956. Hb/RDW remained independently associated with the primary outcome (adjusted odds ratio: 0.023, 95% CI: 0.007–0.073; P < 0.001). It performed better than Hb alone and similarly to RDW, with the greatest incremental discrimination when added to the clinical base model. Lower values were also observed in variceal bleeding. CONCLUSION: Lower Hb/RDW at presentation was independently associated with adverse outcomes in UGIB and may serve as an adjunctive early triage marker.
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-14
Rational Use of Analgesic Agents in Elderly Patients: Implications of the Beers Criteria and STOPP/START Algorithms
Introduction/Objective: Pain affects approximately 30% of community-dwelling older adults and more than half of nursing-home residents but remains undertreated because age-related pharmacokinetic and pharmacodynamic changes render standard analgesic dosing hazardous. This review synthesises the evidence on rational analgesic prescribing in older adults, comparing the American Geriatrics Society 2023 Beers Criteria with STOPP/START version 3. Methods: In this structured narrative review, PubMed/MEDLINE, Embase and the Cochrane Library were searched (January 2000-May 2026), combining analgesic-class terms with the Beers Criteria, STOPP/START, potentially inappropriate medications, deprescribing and older age. Systematic reviews, meta-analyses, randomised trials, large observational studies and guidelines in English were eligible; studies confined to patients younger than 65 years were excluded. Results: Analgesics are principal drivers of inappropriate prescribing: STOPP/START version 3 identified at least one potentially inappropriate medication in 73% of geriatric outpatients versus 56% under version 2, NSAIDs and aspirin being the most prevalent new criteria. The Beers Criteria designate meperidine, non-selective oral NSAIDs, anticholinergic tricyclic antidepressants, and opioid-benzodiazepine or opioidgabapentinoid combinations as highest risk; meperidine is most strongly associated with unplanned hospitalisation (OR 2.37). Discussion: The instruments are complementary, not interchangeable: the Beers Criteria offer broader drug-disease coverage but are aligned with the United States formulary, whereas STOPP/START is bidirectional and more prescriptive on dose and renal thresholds. Neither has been shown to reduce falls, hospitalisation or mortality in adequately powered trials. Conclusion: Stepwise multimodal analgesia beginning with paracetamol and topical agents, initiated at low doses and titrated slowly, with comprehensive geriatric assessment and regular medication review, remains the evidence-based standard of care.
- 9 October 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-14
Rational Use of Analgesic Agents in Elderly Patients: Implications of the Beers Criteria and STOPP/START Algorithms
Introduction/Objective: Pain affects approximately 30% of community-dwelling older adults and more than half of nursing-home residents but remains undertreated because age-related pharmacokinetic and pharmacodynamic changes render standard analgesic dosing hazardous. This review synthesises the evidence on rational analgesic prescribing in older adults, comparing the American Geriatrics Society 2023 Beers Criteria with STOPP/START version 3. Methods: In this structured narrative review, PubMed/MEDLINE, Embase and the Cochrane Library were searched (January 2000-May 2026), combining analgesic-class terms with the Beers Criteria, STOPP/START, potentially inappropriate medications, deprescribing and older age. Systematic reviews, meta-analyses, randomised trials, large observational studies and guidelines in English were eligible; studies confined to patients younger than 65 years were excluded. Results: Analgesics are principal drivers of inappropriate prescribing: STOPP/START version 3 identified at least one potentially inappropriate medication in 73% of geriatric outpatients versus 56% under version 2, NSAIDs and aspirin being the most prevalent new criteria. The Beers Criteria designate meperidine, non-selective oral NSAIDs, anticholinergic tricyclic antidepressants, and opioid-benzodiazepine or opioidgabapentinoid combinations as highest risk; meperidine is most strongly associated with unplanned hospitalisation (OR 2.37). Discussion: The instruments are complementary, not interchangeable: the Beers Criteria offer broader drug-disease coverage but are aligned with the United States formulary, whereas STOPP/START is bidirectional and more prescriptive on dose and renal thresholds. Neither has been shown to reduce falls, hospitalisation or mortality in adequately powered trials. Conclusion: Stepwise multimodal analgesia beginning with paracetamol and topical agents, initiated at low doses and titrated slowly, with comprehensive geriatric assessment and regular medication review, remains the evidence-based standard of care.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-12
Safety and Efficacy of Therapeutic Agents in Viral Pneumonia in Immunosuppressed Patients
Introduction/Objective: Immunosuppressed Patients (ISP) — defined by congenital or acquired deficiencies in systemic defense mechanisms — are disproportionately susceptible to viral respiratory infections. Agents such as SARS-CoV-2, Respiratory Syncytial Virus (RSV), influenza A and B, and Cytomegalovirus (CMV) cause significant morbidity in both immunocompetent and immunosuppressed individuals. Clinical manifestations range from mild influenza-like illness to severe pneumonia, respiratory failure, multiorgan dysfunction, and concurrent bacterial infections. Methods: A narrative synthesis of the literature was performed using Medline, CINAHL, Web of Science, and Scopus using relevant keywords ("immunosuppressed patients", "pneumonia", "lung infection", "antiviral", "cytomegalovirus", "influenza", "RSV") for publications between January 2000 and March 2026. Where available, Cochrane systematic reviews, meta-analyses, and high-quality randomised controlled trials were given precedence in the narrative synthesis; systematic review and meta-analytic procedures, including PRISMA guidelines, were not applied. Case reports, editorials, and opinion articles were excluded, other than a small number of case series describing rare therapeutic strategies for which no higher-level evidence was available. Evidence was collated narratively and presented in tabular format. Results: Although numerous antiviral compounds have been developed and studied, the optimal agent for managing severe viral infections in ISP remains uncertain. Empiric oseltamivir for influenza is typically initiated immediately upon clinical suspicion. Other antivirals — including ganciclovir for CMV, cidofovir for adenovirus, and ribavirin for RSV or parainfluenza — are generally reserved for confirmed or highly suspected infections in high-risk populations. The safety profile of each agent must be evaluated individually before initiating the treatment. Discussion: Direct-acting antivirals achieve faster virologic clearance but do not consistently reduce shortterm mortality in ISP. Antiviral selection requires integration of pathogen identity, timing of therapy, underlying immune deficit, and individual risk-benefit assessment. Novel agents and combination strategies warrant further investigation in this population. Conclusion: ISP with viral pneumonia represents a clinically complex, high-risk group requiring individualized treatment strategies, including antiviral agents, vigilant safety monitoring, and proactive preventive measures, especially vaccination. Virologic clearance benefits associated with direct-acting antivirals such as remdesivir do not consistently translate into a short-term mortality benefit, underscoring the need for outcome- specific interpretation of the evidence. A nuanced understanding of the available antiviral armamentarium is essential to optimise outcomes in this vulnerable population.
- 29 September 2026
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 32, 1-12
Safety and Efficacy of Therapeutic Agents in Viral Pneumonia in Immunosuppressed Patients
Introduction/Objective: Immunosuppressed Patients (ISP) — defined by congenital or acquired deficiencies in systemic defense mechanisms — are disproportionately susceptible to viral respiratory infections. Agents such as SARS-CoV-2, Respiratory Syncytial Virus (RSV), influenza A and B, and Cytomegalovirus (CMV) cause significant morbidity in both immunocompetent and immunosuppressed individuals. Clinical manifestations range from mild influenza-like illness to severe pneumonia, respiratory failure, multiorgan dysfunction, and concurrent bacterial infections. Methods: A narrative synthesis of the literature was performed using Medline, CINAHL, Web of Science, and Scopus using relevant keywords ("immunosuppressed patients", "pneumonia", "lung infection", "antiviral", "cytomegalovirus", "influenza", "RSV") for publications between January 2000 and March 2026. Where available, Cochrane systematic reviews, meta-analyses, and high-quality randomised controlled trials were given precedence in the narrative synthesis; systematic review and meta-analytic procedures, including PRISMA guidelines, were not applied. Case reports, editorials, and opinion articles were excluded, other than a small number of case series describing rare therapeutic strategies for which no higher-level evidence was available. Evidence was collated narratively and presented in tabular format. Results: Although numerous antiviral compounds have been developed and studied, the optimal agent for managing severe viral infections in ISP remains uncertain. Empiric oseltamivir for influenza is typically initiated immediately upon clinical suspicion. Other antivirals — including ganciclovir for CMV, cidofovir for adenovirus, and ribavirin for RSV or parainfluenza — are generally reserved for confirmed or highly suspected infections in high-risk populations. The safety profile of each agent must be evaluated individually before initiating the treatment. Discussion: Direct-acting antivirals achieve faster virologic clearance but do not consistently reduce shortterm mortality in ISP. Antiviral selection requires integration of pathogen identity, timing of therapy, underlying immune deficit, and individual risk-benefit assessment. Novel agents and combination strategies warrant further investigation in this population. Conclusion: ISP with viral pneumonia represents a clinically complex, high-risk group requiring individualized treatment strategies, including antiviral agents, vigilant safety monitoring, and proactive preventive measures, especially vaccination. Virologic clearance benefits associated with direct-acting antivirals such as remdesivir do not consistently translate into a short-term mortality benefit, underscoring the need for outcome- specific interpretation of the evidence. A nuanced understanding of the available antiviral armamentarium is essential to optimise outcomes in this vulnerable population.
- 17 September 2026
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 34 (2) , 79
Prasugrel in the management of acute coronary syndromes: a systematic review
- 17 September 2026
- Published by Springer Nature in DARU Journal of Pharmaceutical Sciences
- Vol. 34 (2) , 79
Prasugrel in the management of acute coronary syndromes: a systematic review
- Open Access
- 1 September 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 126
Use of analgesics in older individuals with special emphasis on organ failures: pitfalls and caveats
Pain in older adults is highly prevalent and persistently undertreated, and its management becomes substantially more hazardous when renal, hepatic, or respiratory failure co-exists. Age-related pharmacokinetic changes — reduced hepatic blood flow and cytochrome P450 activity, declining glomerular filtration, and altered body composition — are compounded by pharmacodynamic changes, including heightened central nervous system sensitivity and reduced homeostatic reserve. This narrative review synthesises contemporary evidence and current prescribing frameworks into an organ-failure-stratified approach to analgesic selection. Paracetamol and topical agents remain the safest first-line options across all three organ failure states. Non-steroidal anti-inflammatory drugs should be avoided when the estimated glomerular filtration rate falls below 30 mL/min and are contraindicated in cirrhosis. Opioids remain indispensable for moderate-to-severe pain but require dose reduction, interval extension, and close monitoring: fentanyl and buprenorphine are preferred in renal failure, whereas morphine, codeine, and meperidine should be avoided; all opioid doses must be reduced in hepatic failure; and in respiratory failure or chronic obstructive pulmonary disease opioids should be given at the lowest effective dose and never combined with other central nervous system depressants. Adjuvant analgesics carry agent-specific organ restrictions. Frailty, cognitive impairment, and polypharmacy further modify risk. ‘Start low, go slow’ must be calibrated individually to the type and severity of organ dysfunction present.
- 1 September 2026
- Published by Springer Nature in The Egyptian Journal of Internal Medicine
- Vol. 38 (1) , 126
Open AccessUse of analgesics in older individuals with special emphasis on organ failures: pitfalls and caveats
Pain in older adults is highly prevalent and persistently undertreated, and its management becomes substantially more hazardous when renal, hepatic, or respiratory failure co-exists. Age-related pharmacokinetic changes — reduced hepatic blood flow and cytochrome P450 activity, declining glomerular filtration, and altered body composition — are compounded by pharmacodynamic changes, including heightened central nervous system sensitivity and reduced homeostatic reserve. This narrative review synthesises contemporary evidence and current prescribing frameworks into an organ-failure-stratified approach to analgesic selection. Paracetamol and topical agents remain the safest first-line options across all three organ failure states. Non-steroidal anti-inflammatory drugs should be avoided when the estimated glomerular filtration rate falls below 30 mL/min and are contraindicated in cirrhosis. Opioids remain indispensable for moderate-to-severe pain but require dose reduction, interval extension, and close monitoring: fentanyl and buprenorphine are preferred in renal failure, whereas morphine, codeine, and meperidine should be avoided; all opioid doses must be reduced in hepatic failure; and in respiratory failure or chronic obstructive pulmonary disease opioids should be given at the lowest effective dose and never combined with other central nervous system depressants. Adjuvant analgesics carry agent-specific organ restrictions. Frailty, cognitive impairment, and polypharmacy further modify risk. ‘Start low, go slow’ must be calibrated individually to the type and severity of organ dysfunction present.
- 25 August 2026
- Published by SAGE Publications in Scottish Medical Journal
- Vol. 71 (4) , 136-147
Extracorporeal membrane oxygenation use in trauma and emergency care: An update
Extracorporeal membrane oxygenation (ECMO) has a life-saving role in trauma management, with particular relevance to patients with acute respiratory failure. This narrative review describes the current evidence on the use of ECMO in the resuscitation of major trauma victims presenting with acute respiratory distress syndrome, cardiogenic shock, poisoning, burns, and traumatic brain injury, and highlights recent advances in the field. A comprehensive literature search of PubMed and EMBASE was performed for articles, using the MeSH/keywords. Over the past decade, ECMO has been increasingly applied for trauma management, encompassing both venovenous (VV) and venoarterial (VA) modes. VV-ECMO is primarily utilized in hypoxic respiratory failure following thoracic trauma and is associated with improved in-hospital mortality and higher discharge survival compared to conventional mechanical ventilation. VA-ECMO is reserved for hemodynamic collapse and extracorporeal cardiopulmonary resuscitation, a subset of VA-ECMO used specifically in cardiac arrest. Despite promising outcomes, challenges remain, including anticoagulation management, hemorrhagic complications, and the absence of trauma-specific prognostic models. Emerging applications include ECMO in traumatic brain injury, poisoning, and severe burns. Although ECMO improves outcomes in selected trauma patients, further high-quality studies are needed to define optimal selection criteria and to clarify its role across the spectrum of injuries.
- 25 August 2026
- Published by SAGE Publications in Scottish Medical Journal
- Vol. 71 (4) , 136-147
Extracorporeal membrane oxygenation use in trauma and emergency care: An update
Extracorporeal membrane oxygenation (ECMO) has a life-saving role in trauma management, with particular relevance to patients with acute respiratory failure. This narrative review describes the current evidence on the use of ECMO in the resuscitation of major trauma victims presenting with acute respiratory distress syndrome, cardiogenic shock, poisoning, burns, and traumatic brain injury, and highlights recent advances in the field. A comprehensive literature search of PubMed and EMBASE was performed for articles, using the MeSH/keywords. Over the past decade, ECMO has been increasingly applied for trauma management, encompassing both venovenous (VV) and venoarterial (VA) modes. VV-ECMO is primarily utilized in hypoxic respiratory failure following thoracic trauma and is associated with improved in-hospital mortality and higher discharge survival compared to conventional mechanical ventilation. VA-ECMO is reserved for hemodynamic collapse and extracorporeal cardiopulmonary resuscitation, a subset of VA-ECMO used specifically in cardiac arrest. Despite promising outcomes, challenges remain, including anticoagulation management, hemorrhagic complications, and the absence of trauma-specific prognostic models. Emerging applications include ECMO in traumatic brain injury, poisoning, and severe burns. Although ECMO improves outcomes in selected trauma patients, further high-quality studies are needed to define optimal selection criteria and to clarify its role across the spectrum of injuries.
- 21 August 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (9) , 239
Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring
Background The electrocardiogram (ECG) remains the foremost non-invasive tool for detecting adverse drug effects on cardiac electrophysiology, encompassing QT interval prolongation, torsades de pointes (TdP), atrioventricular (AV) block, and sodium-channel-mediated QRS widening. As polypharmacy becomes ubiquitous — particularly in ageing populations and oncology — clinicians require a structured understanding of drug-ECG interactions to mitigate sudden cardiac death risk. Methods A systematic narrative review was conducted using PubMed, Embase, and the Cochrane Library covering January 2006 to April 2026. Priority was given to meta-analyses, systematic reviews, scientific statements, and guidelines addressing drug-induced ECG changes, QTc measurement methodology, TdP risk stratification, and ECG monitoring protocols. Reference lists of key papers were hand-searched. Seventy references meeting quality and relevance criteria are cited. Results Numerous drug classes — including antiarrhythmics, antibiotics, antipsychotics, antidepressants, antiemetics, and oncology agents — prolong the corrected QT interval primarily through blockade of the cardiac hERG/IKr potassium channel. Modifiable risk factors include hypokalaemia, hypomagnesaemia, bradycardia, and co-prescription of CYP3A4 inhibitors. Female sex, age ≥ 65 years, congenital long QT syndrome carriers, and cardiac failure patients are at disproportionate TdP risk. The validated Tisdale Risk Score enables pre-treatment stratification in hospitalised patients. Drug-specific ECG monitoring protocols with actionable thresholds are summarised. Conclusions Drug-induced ECG changes are common, clinically consequential, and often preventable. Evidence-based monitoring protocols, correction of modifiable risk factors, and prompt recognition of ominous ECG patterns substantially reduce adverse outcomes. Prescriber education across all clinical settings is imperative.
- 21 August 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (9) , 239
Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring
Background The electrocardiogram (ECG) remains the foremost non-invasive tool for detecting adverse drug effects on cardiac electrophysiology, encompassing QT interval prolongation, torsades de pointes (TdP), atrioventricular (AV) block, and sodium-channel-mediated QRS widening. As polypharmacy becomes ubiquitous — particularly in ageing populations and oncology — clinicians require a structured understanding of drug-ECG interactions to mitigate sudden cardiac death risk. Methods A systematic narrative review was conducted using PubMed, Embase, and the Cochrane Library covering January 2006 to April 2026. Priority was given to meta-analyses, systematic reviews, scientific statements, and guidelines addressing drug-induced ECG changes, QTc measurement methodology, TdP risk stratification, and ECG monitoring protocols. Reference lists of key papers were hand-searched. Seventy references meeting quality and relevance criteria are cited. Results Numerous drug classes — including antiarrhythmics, antibiotics, antipsychotics, antidepressants, antiemetics, and oncology agents — prolong the corrected QT interval primarily through blockade of the cardiac hERG/IKr potassium channel. Modifiable risk factors include hypokalaemia, hypomagnesaemia, bradycardia, and co-prescription of CYP3A4 inhibitors. Female sex, age ≥ 65 years, congenital long QT syndrome carriers, and cardiac failure patients are at disproportionate TdP risk. The validated Tisdale Risk Score enables pre-treatment stratification in hospitalised patients. Drug-specific ECG monitoring protocols with actionable thresholds are summarised. Conclusions Drug-induced ECG changes are common, clinically consequential, and often preventable. Evidence-based monitoring protocols, correction of modifiable risk factors, and prompt recognition of ominous ECG patterns substantially reduce adverse outcomes. Prescriber education across all clinical settings is imperative.
- Open Access
- 1 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Brachiocephalic vein distensibility during passive leg raising in healthy adults
Passive leg raising (PLR) is a validated test of fluid responsiveness, but the value of brachiocephalic vein (BCV) distensibility as an ultrasound marker remains uncertain. In this prospective study, 129 volunteers were assessed for eligibility and 122 were analyzed (45 nonfasting controls, 77 fasting). Cardiac output (CO) was measured before and after PLR by echocardiography, and BCV distensibility was calculated from respiratory diameter variation. PLR increased CO in both groups ( P < 0.001). Median ΔCO was lower in fasting participants than in controls (21.05 [12.93–37.32] vs. 29.88 [22.13–39.86], P = 0.038), with lower responder rates at ΔCO ≥ 10% (79.2% vs. 95.6%, P = 0.016) and ΔCO ≥ 15% (74.0% vs. 91.1%, P = 0.032). ΔBCV distensibility did not differ between groups and was not associated with ΔCO overall (Spearman r = 0.148, P = 0.105). ROC analysis showed poor discrimination (AUC 0.38 overall, 0.51 in controls, 0.31 in fasting participants for ΔCO ≥ 15%), and exploratory adjusted analyses did not support an independent association between fasting status and responder status. BCV distensibility showed limited value and poor discriminatory performance as a marker of PLR-induced cardiac output change in spontaneously breathing healthy adults.
- 1 August 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessBrachiocephalic vein distensibility during passive leg raising in healthy adults
Passive leg raising (PLR) is a validated test of fluid responsiveness, but the value of brachiocephalic vein (BCV) distensibility as an ultrasound marker remains uncertain. In this prospective study, 129 volunteers were assessed for eligibility and 122 were analyzed (45 nonfasting controls, 77 fasting). Cardiac output (CO) was measured before and after PLR by echocardiography, and BCV distensibility was calculated from respiratory diameter variation. PLR increased CO in both groups ( P < 0.001). Median ΔCO was lower in fasting participants than in controls (21.05 [12.93–37.32] vs. 29.88 [22.13–39.86], P = 0.038), with lower responder rates at ΔCO ≥ 10% (79.2% vs. 95.6%, P = 0.016) and ΔCO ≥ 15% (74.0% vs. 91.1%, P = 0.032). ΔBCV distensibility did not differ between groups and was not associated with ΔCO overall (Spearman r = 0.148, P = 0.105). ROC analysis showed poor discrimination (AUC 0.38 overall, 0.51 in controls, 0.31 in fasting participants for ΔCO ≥ 15%), and exploratory adjusted analyses did not support an independent association between fasting status and responder status. BCV distensibility showed limited value and poor discriminatory performance as a marker of PLR-induced cardiac output change in spontaneously breathing healthy adults.